🔎 Trials Near Me

Beranda › Limfoma Sel B Besar Difus › Louisiana

Uji klinis Limfoma Sel B Besar Difus di Louisiana

6 studi untuk Limfoma Sel B Besar Difus mencari peserta di lokasi di Louisiana.

Kota di Louisiana

Teks studi resmi (Bahasa Inggris)

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Mary Bird Perkins Cancer Center, Baton Rouge
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180), Baton Rouge
  • Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209), Monroe
  • Ochsner Clinic Foundation ( Site 0189), New Orleans
  • dan 1 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06890884

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  • Mary Bird Perkins Cancer Ctr, Baton Rouge
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06806033

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Louisiana State University Health Sciences Center, Shreveport
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  • Tulane Cancer Center Office of Clinical Research, New Orleans
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Apr 2023 · NCT04920617

Dari ClinicalTrials.gov, data diambil 4 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.